Jefferies lowers Perrigo stock price target to $14 on weak quarter

Jefferies cut Perrigo’s price target to $14 from $16 while keeping a Hold rating, citing a soft first quarter, consumption headwinds, and retailer destocking. Perrigo still reported Q1 2026 EPS of $0.43, above the $0.33 consensus, but revenue missed at $969 million versus $1.03 billion expected. Management maintained full-year guidance and expects improvement in the second half as distribution wins and innovation materialize.

Analysis

The setup is less about one weak print and more about a prolonged inventory digestion cycle that can suppress sell-through for multiple quarters. Retailers typically stay cautious until they see two clean periods of improving take rates, so the real catalyst is not near-term EPS beats but evidence that promo intensity is easing and channel inventories have normalized. That makes this more of a 2H story than a 2-3 week trading event, and the market will likely punish any signs that distribution gains are being offset by price compression.

Second-order, the pressure is not isolated to this name: OTC and private-label adjacent suppliers are likely to face the same destocking overhang, which means the group can underwrite higher volatility even if individual companies hold guidance. A dividend screen is helping support valuation, but that support is fragile if working capital remains elevated and free cash flow lags earnings. If management has to fund the payout while demand is still soft, the market will increasingly focus on balance-sheet optionality rather than headline multiple support.

The contrarian view is that the selloff may be overdone if consumption is bottoming faster than expected and the company’s innovation/distribution pipeline begins to show up sequentially by late summer. In that case, the stock can re-rate quickly because expectations are already depressed and any stabilization in retailer orders would compress the bear case. The key is that this is a timing trade: the upside is likely concentrated in the next 1-2 quarters if channel checks turn, while the downside extends if destocking persists into the holiday build.

For the broader market, this reads as a cautionary signal on defensive consumer names exposed to discretionary OTC behavior and retailer inventory swings. If PRGO is a read-through, the winners are the names with cleaner direct-to-consumer or subscription exposure, while traditional shelf-space businesses remain hostage to retailer behavior and trade spend. That dynamic favors relative value longs in higher-quality consumer health rather than outright beta.

Key Decisions for Investors

• Stay short/underweight PRGO into the next 1-2 quarterly channel checks; use any relief rally toward the revised target area to add, with downside risk tied to a real stabilization in retailer orders.
• Pair trade: long higher-quality consumer health with cleaner demand visibility versus short PRGO for 1-2 quarters; the thesis is dispersion from inventory normalization, not category recovery.
• If holding PRGO, consider selling covered calls over the next 6-10 weeks to monetize elevated event risk while waiting for proof of 2H improvement; this improves carry if the stock remains range-bound.
• For tactical longs, wait for evidence of sequential improvement in POS and inventory before buying PRGO; otherwise the risk/reward is poor because guidance support can still decay if destocking extends into 2H.